NCT01620437View on ClinicalTrials.gov

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Japanese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 29, 2003

Primary Completion Date

December 30, 2003

Study Completion Date

December 30, 2003

Conditions
DiabetesHealthy
Interventions
DRUG

biphasic insulin aspart 50

A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-21 days will take place between dosing visits

Trial Locations (1)

1000005

Novo Nordisk Investigational Site, Tokyo

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY